Literature DB >> 20557849

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

D Strumberg1, B Schultheis, M E Scheulen, R A Hilger, J Krauss, N Marschner, F Lordick, F Bach, D Reuter, L Edler, K Mross.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20557849     DOI： 10.5414/cpp48473

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  6 in total

1.  A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.

Authors:  Benoit You; Anthony Brade; Joao M Magalhaes; Lillian L Siu; Amit Oza; Sonya Lovell; Lisa Wang; David W Hedley; Leonardo V Nicacio; Eric X Chen
Journal:  Invest New Drugs       Date:  2010-05-08       Impact factor: 3.850

2.  Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.

Authors:  Dan Su; Shun-Chang Jiao; Li-Jie Wang; Wei-Wei Shi; Yan-Yan Long; Juan Li; Li Bai
Journal:  Tumour Biol       Date:  2013-10-19

3.  Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China.

Authors:  Weilan Wang; Man Zhu; Daihong Guo; Chao Chen; Dongxiao Wang; Fei Pei; Liang Ma
Journal:  Iran J Public Health       Date:  2013-05-01       Impact factor: 1.429

4.  Pancreatic cancer: chemotherapy and radiotherapy.

Authors:  Ake Andrén-Sandberg
Journal:  N Am J Med Sci       Date:  2011-01

5.  Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.

Authors:  Xin Tian; Ying Xuan; Rong Wu; Song Gao
Journal:  Cancer Manag Res       Date:  2020-05-11       Impact factor: 3.989

6.  Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety.

Authors:  Wendy Bernhard; Kris Barreto; Ayman El-Sayed; Carolina Gonzalez; Raja Solomon Viswas; Darien Toledo; Angel Casaco; John DeCoteau; Humphrey Fonge; Clarence Ronald Geyer
Journal:  BMC Cancer       Date:  2021-03-12       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.